Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer

Area of Science:

• Biochemistry
• Oncology
• Drug Discovery

Background:

• Fatty acid synthase (FASN) is upregulated in most human carcinomas, including breast cancer.
• FASN expression is linked to HER2 signaling pathways, making it a target for cancer therapy.
• Current FASN inhibitors face challenges like anorexia, weight loss, and poor in vivo performance.

Purpose of the Study:

• To design and develop a novel synthetic inhibitor of Fatty Acid Synthase (FASN).
• To evaluate the in vitro and in vivo efficacy of the lead compound G28UCM.
• To explore a new therapeutic strategy for FASN(+) and HER2(+) breast cancer.

Main Methods:

• Design and synthesis of novel FASN inhibitors.
• In vitro assays to assess enzyme inhibition and cellular activity.
• In vivo studies using a human breast cancer model.

Main Results:

• G28UCM demonstrated potent in vitro inhibition of FASN.
• The compound exhibited significant anti-tumor activity in vivo.
• Efficacy was observed in a breast cancer model characterized by FASN and HER2 positivity.

Conclusions:

• G28UCM represents a promising novel synthetic FASN inhibitor.
• This compound offers potential therapeutic benefits for FASN(+) and HER2(+) breast cancers.
• Further development of G28UCM could overcome limitations of existing FASN inhibitors.